Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$5.95 - $14.3 $170,467 - $409,695
-28,650 Reduced 43.34%
37,450 $223,000
Q2 2022

Aug 15, 2022

SELL
$10.6 - $13.28 $7.01 Million - $8.78 Million
-661,136 Reduced 90.91%
66,100 $747,000
Q1 2022

May 16, 2022

SELL
$10.37 - $12.73 $946,532 - $1.16 Million
-91,276 Reduced 11.15%
727,236 $8.5 Million
Q4 2021

Feb 14, 2022

SELL
$10.21 - $15.27 $3.32 Million - $4.96 Million
-324,713 Reduced 28.4%
818,512 $9.2 Million
Q3 2021

Nov 15, 2021

SELL
$14.07 - $17.3 $13.4 Million - $16.5 Million
-951,345 Reduced 45.42%
1,143,225 $16.8 Million
Q2 2021

Aug 16, 2021

BUY
$16.62 - $18.94 $12.3 Million - $14 Million
740,734 Added 54.71%
2,094,570 $36.5 Million
Q1 2021

May 14, 2021

SELL
$15.15 - $19.78 $4.41 Million - $5.76 Million
-291,330 Reduced 17.71%
1,353,836 $22.9 Million
Q4 2020

Feb 12, 2021

BUY
$16.86 - $19.67 $3.79 Million - $4.42 Million
224,815 Added 15.83%
1,645,166 $30.4 Million
Q3 2020

Nov 13, 2020

BUY
$15.4 - $20.16 $1.27 Million - $1.66 Million
82,561 Added 6.17%
1,420,351 $24.1 Million
Q2 2020

Aug 14, 2020

BUY
$18.24 - $21.45 $17 Million - $20 Million
932,601 Added 230.16%
1,337,790 $24.8 Million
Q1 2020

May 15, 2020

SELL
$16.28 - $25.63 $5,388 - $8,483
-331 Reduced 0.08%
405,189 $8.16 Million
Q3 2019

Nov 14, 2019

SELL
$19.85 - $22.76 $15,780 - $18,094
-795 Reduced 0.2%
405,520 $8.13 Million
Q2 2019

Aug 14, 2019

SELL
$17.59 - $21.1 $27,071 - $32,472
-1,539 Reduced 0.38%
406,315 $8.57 Million
Q1 2019

May 15, 2019

SELL
$18.01 - $20.11 $32,994 - $36,841
-1,832 Reduced 0.45%
407,854 $8.2 Million
Q4 2018

Feb 14, 2019

BUY
$17.44 - $21.53 $7.14 Million - $8.82 Million
409,686 New
409,686 $7.52 Million

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.31B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.